What question did this study set out to answer?

To review the preclinical rationale, clinical trial data, toxicity management, and resistance mechanisms of blinatumomab in patients with acute lymphoblastic leukemia.

April 4, 2016Therapeutic Advances in HematologyOpen Access

The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia

View Full Paper

Ask AI

Bookmark

Authors

JBJonathan BenjaminRapt Therapeutics (United States)ASAnthony S. SteinUniversity of Hohenheim

Discussion

Member takes

Implication

Review demonstrates clinical efficacy and manageable toxicities of blinatumomab in relapsed/refractory acute lymphoblastic leukemia, highlighting its role before stem cell transplantation.

Key Points

To review the preclinical rationale, clinical trial data, toxicity management, and resistance mechanisms of blinatumomab in patients with acute lymphoblastic leukemia.
Evaluated preclinical mechanisms of action for bispecific T-cell engager (BiTE) antibodies co-targeting CD19 and CD3.
Synthesized clinical trial outcomes across adult and pediatric populations with relapsed/refractory, minimal residual disease-positive, and Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.
A pivotal phase II trial of 189 adults with relapsed/refractory B-cell acute lymphoblastic leukemia demonstrated a complete remission or complete remission with partial hematologic recovery (CR/CRh) rate of 43% after two cycles.
Adverse events include cytokine-release syndrome and neurologic toxicities, with cytokine-release syndrome successfully mitigated using step-up dosing regimens and dexamethasone.

Cite This Study

Benjamin et al. (2016) studied this question.

synapsesocial.com/papers/69e1bc76aba40719165f6aaf https://doi.org/10.1177/2040620716640422

View Full Paper

Ask AI

Bookmark

Implication

Review demonstrates clinical efficacy and manageable toxicities of blinatumomab in relapsed/refractory acute lymphoblastic leukemia, highlighting its role before stem cell transplantation.

The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider